202 related articles for article (PubMed ID: 31451564)
21. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
[TBL] [Abstract][Full Text] [Related]
23. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
26. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
27. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
28. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity.
Lamb R; Lehn S; Rogerson L; Clarke RB; Landberg G
Cell Cycle; 2013 Aug; 12(15):2384-94. PubMed ID: 23839043
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.
Ramos N; Baquero-Buitrago J; Ben Youss Gironda Z; Wadghiri YZ; Reiner T; Boada FE; Carlucci G
J Nucl Med; 2020 Mar; 61(3):437-442. PubMed ID: 31481582
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
32. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
33. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
34. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
35. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
36. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Costa C; Wang Y; Ly A; Hosono Y; Murchie E; Walmsley CS; Huynh T; Healy C; Peterson R; Yanase S; Jakubik CT; Henderson LE; Damon LJ; Timonina D; Sanidas I; Pinto CJ; Mino-Kenudson M; Stone JR; Dyson NJ; Ellisen LW; Bardia A; Ebi H; Benes CH; Engelman JA; Juric D
Cancer Discov; 2020 Jan; 10(1):72-85. PubMed ID: 31594766
[TBL] [Abstract][Full Text] [Related]
37. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
39. Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Owsley J; Jimeno A; Diamond JR
Drugs Today (Barc); 2016 Feb; 52(2):119-29. PubMed ID: 27092341
[TBL] [Abstract][Full Text] [Related]
40. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
